On September 15, 2025, in Taipei, a major biologics CDMO company, Mycenax Biotech Inc. (TWO:4726), headquartered in Taiwan, revealed a new strategic partnership. The company has joined forces with SPERA PHARMA Inc., a renowned Japanese expert in pharmaceutical Chemistry, Manufacturing, and Controls (CMC). This collaboration is set to pave the way for enhanced capabilities and innovation in the pharmaceutical industry.